STOCK TITAN

Harvard Biosci - HBIO STOCK NEWS

Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.

Overview of Harvard Bioscience (HBIO)

Harvard Bioscience, Inc. is a global leader in the development, manufacturing, and marketing of specialized scientific instruments and technologies that empower advancements in life sciences research. The company provides essential tools and platforms that enable preclinical testing, drug discovery, and fundamental biological research. With a diverse portfolio of products, Harvard Bioscience serves pharmaceutical companies, biotechnology firms, academic institutions, and government laboratories worldwide. Its solutions are instrumental in fields such as neuroscience, toxicology, organoid research, and preclinical drug development.

Core Business and Product Offerings

The company’s product portfolio is designed to address the complex needs of life science researchers. Key offerings include:

  • Ponemah™ Data Management Platform: A GLP-compliant, integrated solution for preclinical data collection, analysis, and reporting. This platform supports telemetry systems like the SoHo™ implantable telemetry solution and the VivaMARS™ activity monitoring system.
  • Mesh Microelectrode Array (MEA) Platform: An advanced tool for real-time electrophysiology measurements within organoids, supporting applications in neuroscience, safety pharmacology, and toxicology.
  • Behavioral Analysis Tools: Systems like VivaMARS™ provide high-throughput, automated solutions for behavioral testing in neuropharmacology and neurotoxicology research.
  • Patch Clamp and Electrophysiology Systems: Cutting-edge instruments for in-vitro and in-vivo neuroscience research, enabling precise studies of ion channels, neural activity, and more.

Harvard Bioscience’s products are distributed through direct sales, online platforms, and partnerships with leading distributors such as Thermo Fisher Scientific and VWR. The company’s brands, including Harvard Apparatus, DSI, Buxco, and Multichannel Systems, are recognized for their reliability and innovation in the scientific community.

Global Presence and Market Reach

Headquartered in Holliston, Massachusetts, Harvard Bioscience operates across North America, Europe, and China, with manufacturing facilities in the United States, the United Kingdom, Germany, and Spain. Its products are sold in over 100 countries, reflecting a strong global footprint. Key markets include pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic institutions conducting cutting-edge research in life sciences.

Competitive Positioning

Harvard Bioscience differentiates itself through its focus on integrated solutions that streamline research workflows and enhance data quality. Its platforms, such as Ponemah, combine hardware and software to deliver comprehensive, GLP-compliant solutions for preclinical testing. The company’s emphasis on emerging fields like organoid research and machine learning-based data analysis positions it as a forward-thinking player in a competitive landscape. While it faces competition from larger corporations like Thermo Fisher Scientific and GE Healthcare, Harvard Bioscience’s niche focus and continuous innovation provide a competitive edge.

Significance in the Life Sciences Industry

Harvard Bioscience plays a critical role in advancing scientific discovery and therapeutic development. Its tools and technologies enable researchers to conduct sophisticated experiments with precision and efficiency, contributing to breakthroughs in areas like neuroscience, toxicology, and drug development. By addressing the evolving needs of the scientific community, Harvard Bioscience supports the acceleration of life-saving therapies and innovations in healthcare.

Conclusion

Harvard Bioscience, Inc. is a cornerstone in the life sciences ecosystem, providing indispensable tools and technologies that drive research and innovation. Its commitment to quality, innovation, and customer-centric solutions ensures its continued relevance in a dynamic and demanding industry.

Rhea-AI Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) to Present at Benchmark Company 12th Annual Discovery One-on-One Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) announced that Chairman and CEO Jim Green, along with CFO Jennifer Cote, will present at the Southwest IDEAS Investor Conference on November 16, 2023. The presentation will be available for replay on the company's website. One-on-one meetings with investors will also be hosted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
-
Rhea-AI Summary
Harvard Bioscience, Inc. (HBIO) reported Q3 revenues of $25.4 million with a gross margin of 58.1%. GAAP operating loss was $0.9 million, adjusted operating income was $1.8 million. Debt was reduced by $8.3 million through Q3. Q3 revenues declined by 6% compared to the same period last year. Adjusted EBITDA for Q3 was $2.2 million, and cash provided by operations was $4.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
Rhea-AI Summary
Harvard Bioscience, Inc. will showcase its latest product innovations at the Society for Neuroscience (SfN) conference. The new innovations include the SoHo implantable telemetry solution for small animal models and the VivaMARS high-capacity behavior monitoring system. The company will also exhibit its first organoid-centric mesh Microelectrode Array (MEA) for capturing electrophysiology measurements from inside the organoid in real time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
-
Rhea-AI Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for Q3 2023 on November 7, 2023. A conference call will be held at 8:00 a.m. Eastern Time. Participants can register to join the call and ask questions. An audio-only webcast will also be available. Financial information will be accessible on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
-
Rhea-AI Summary
Harvard Bioscience and Etisense partner to offer DECRO telemetry jackets and software in North American and European markets
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Harvard Bioscience, Inc. will announce its financial results for Q2 2023 on August 8, 2023. A conference call will be held to discuss the results at 8:00 a.m. Eastern Time. Participants can register to join the call and ask questions. Financial information will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none

FAQ

What is the current stock price of Harvard Biosci (HBIO)?

The current stock price of Harvard Biosci (HBIO) is $0.82 as of March 3, 2025.

What is the market cap of Harvard Biosci (HBIO)?

The market cap of Harvard Biosci (HBIO) is approximately 36.0M.

What does Harvard Bioscience specialize in?

Harvard Bioscience specializes in developing and manufacturing scientific instruments and technologies for life sciences research, including preclinical testing and drug discovery.

Who are the primary customers of Harvard Bioscience?

The company's customers include pharmaceutical companies, biotechnology firms, academic institutions, government laboratories, and contract research organizations (CROs).

What are the key products offered by Harvard Bioscience?

Key products include the Ponemah™ data management platform, Mesh Microelectrode Array (MEA) systems, VivaMARS™ behavioral analysis tools, and patch clamp electrophysiology systems.

How does Harvard Bioscience differentiate itself in the market?

The company differentiates itself through integrated solutions like Ponemah, which streamline research workflows, and its focus on emerging fields such as organoid research and machine learning-based data analysis.

Where does Harvard Bioscience operate?

Harvard Bioscience operates globally, with manufacturing facilities in the U.S., U.K., Germany, and Spain, and sales in over 100 countries.

What industries does Harvard Bioscience serve?

The company serves industries involved in life sciences research, including pharmaceuticals, biotechnology, neuroscience, toxicology, and academic research.

What is the significance of the Ponemah™ platform?

The Ponemah™ platform is a GLP-compliant data management system that integrates with telemetry and behavioral analysis tools, enabling efficient data collection, analysis, and reporting for preclinical studies.

What is the focus of Harvard Bioscience's organoid research tools?

The company’s Mesh Microelectrode Array (MEA) platform supports organoid research by providing real-time electrophysiology measurements for applications in neuroscience, toxicology, and safety pharmacology.
Harvard Biosci

Nasdaq:HBIO

HBIO Rankings

HBIO Stock Data

36.03M
40.47M
7.23%
75.94%
1.8%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States
HOLLISTON